Clinical-stage pharmaceutical research company MimiVax Inc announced on Wednesday that its now fully enrolled Phase 2b clinical trial of SurVaxM in glioblastoma has successfully progressed following the first interim analysis of trial data.

This analysis, conducted as part of the clinical development programme, has provided valuable insights that support the continued advancement of the SURVIVE trial, the company said.

The purpose of the study is to determine whether adding SurVaxM to standard-of-care (resection, radiation/chemotherapy) is better than standard treatment alone for patients with newly diagnosed glioblastoma.

MimiVax said that while it is unable to disclose specific details about the interim analysis due to US regulatory requirements, it remains confident in the potential of SurVaxM and is committed to advancing the study as planned.

Based on the results of the recent interim futility analysis, and ongoing review by the study's Independent Data Safety Monitoring Committee, the SURVIVE trial will continue as designed without modification.

The clinical trial is designed to evaluate the safety, efficacy and overall benefit of SurVaxM in patients with newly diagnosed glioblastoma who receive standard-of-care treatment combined with SurVaxM at 11 participating major cancer centres in the United States.